Liminatus Pharma, Inc. — Form 8-K Summary
Reporting context: Current report concerning Nasdaq listing compliance. Nasdaq notice was received September 24, 2026; the report was signed and the related press release was dated September 29, 2026.
Key development
Nasdaq determined that Liminatus regained compliance with the minimum bid price requirement for the Nasdaq Capital Market. The closing bid price was above $1.00 for 13 consecutive trading days, August 21 through September 9, 2026, and Nasdaq closed the matter.
The company had received a deficiency notice on January 15, 2026, after its closing bid price remained below $1.00 for 30 consecutive business days. Following an appeal, Nasdaq transferred the company to the Capital Market effective August 4 and gave it until September 3 to demonstrate compliance. The company effected a 1-for-50 reverse stock split after market close on August 20.
Financial and operating information
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics. It provides no comparable-period financial results.
Outlook, risks, and other disclosures
No financial guidance or business outlook is provided. The filing reports resolution of the cited bid-price deficiency but does not address other listing requirements or future compliance. The company’s common stock (LIMN) and warrants (LIMNW) are listed on Nasdaq. The company is identified as an emerging growth company.
The press release furnished as Exhibit 99.1 is not deemed filed for purposes of Exchange Act Section 18, except as expressly stated in a subsequent filing.
Facts investors should verify
- Whether the company continues to satisfy all Nasdaq listing requirements after regaining bid-price compliance.
- The effect of the 1-for-50 reverse stock split on share count, trading, and any outstanding securities.
- Any additional details in Exhibit 99.1 and subsequent company filings.